Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)

Trial Profile

Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Arimoclomol (Primary)
  • Indications Inclusion body myositis
  • Focus Registrational; Therapeutic Use
  • Sponsors Orphazyme
  • Most Recent Events

    • 15 Dec 2017 According to an Orphazyme media release, trial is intended to support a registration of arimoclomol for the treatment of sIBM and results are expected in H1 2020.
    • 24 Oct 2017 This study, if positive, will form the basis for a single study filing for Sporadic Inclusion Body Myositis (IBM). The company expects to complete this trial by the end of 2020.
    • 30 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top